In complex drug development, AI can make individual tasks faster, but the harder problem is proving whether that speed becomes real enterprise value.
Using token consumption to drive AI adoption can create a leaderboard for spending, not a scorecard for value.
Layoffs can make an AI program look decisive, but the stronger signal is whether a company is reskilling staff, redesigning workflows, and creating new roles that can actually use the technology.